Publications

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C et al..  2016.  Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.. Sci Rep. 6:24146.

Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al..  2005.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.. Cancer Res. 65(13):5561-70.

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA.  2009.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice.. Eur Urol. 56(2):275-86.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R et al..  2005.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.. Science. 310(5748):644-8.

Svensson MA, Lafargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS et al..  2011.  Testing mutual exclusivity of ETS rearranged prostate cancer.. Lab Invest. 91(3):404-12.

Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M et al..  2009.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 27(21):3459-64.

Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.  2004.  Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.. J Natl Cancer Inst. 96(11):834-43.

Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA et al..  2004.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.. Cancer Res. 64(24):9209-16.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.

Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA.  2007.  Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. Cancer Res. 67(21):10296-303.

Setlur SR, Rubin MA.  2005.  Current thoughts on the role of the androgen receptor and prostate cancer progression.. Adv Anat Pathol. 12(5):265-70.

Schlick B, Massoner P, Lueking A, Charoentong P, Blattner M, Schaefer G, Marquart K, Theek C, Amersdorfer P, Zielinski D et al..  2016.  Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.. PLoS One. 11(2):e0147739.

Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS et al..  2010.  FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data.. Genome Biol. 11(10):R104.

Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami H-O, Fall K, Mucci LA et al..  2010.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.. BMC Med Genomics. 3:8.

Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM et al..  2004.  JAGGED1 expression is associated with prostate cancer metastasis and recurrence.. Cancer Res. 64(19):6854-7.

Sailer V, Pauli C, Merzier EC, Mosquera JMiguel, Beltran H, Rubin MA, Rao RA.  2017.  On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.. Anticancer Res. 37(4):1569-1573.

Rubin MA, Allory Y, Molinié V, Leroy X, Faucon H, Vacherot F, Huang W, Kuten A, Salomon L, Rebillard X et al..  2005.  Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome.. Urology. 66(5):930-4.

Rubin MA, Elemento O, Sboner A, Imielinski M, Pisapia D, Fernandes H, Zia H, Huang L, Tavassoli P, Kluk M.  2016.  The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretation. JAMIA.

Rubin MA.  2015.  Toward a prostate cancer precision medicine.. Urol Oncol. 33(2):73-4.

Rubin MA, Maher CA, Chinnaiyan AM.  2011.  Common gene rearrangements in prostate cancer.. J Clin Oncol. 29(27):3659-68.

Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami H-O et al..  2005.  Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.. Cancer Epidemiol Biomarkers Prev. 14(6):1424-32.

Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD, Chinnaiyan AM, Rimm DL.  2004.  Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements.. Am J Pathol. 164(3):831-40.

Rubin MA, Chinnaiyan AM.  2006.  Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.. Lab Invest. 86(11):1099-102.

Rubin MA, Girelli G, Demichelis F.  2016.  Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.. Eur Urol. 69(4):557-60.